Kodiak Sciences Inc KOD:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 4:44 PM EDT33.91
+0.04 (+0.12%)
+0.04 (+0.12%)Volume
2,058
Close
33.87+0.65 (+1.97%)
+0.65 (+1.97%)Volume
916,637
52 week range
3.43 - 47.84
- Open33.47
- Day High35.32
- Day Low32.64
- Prev Close33.22
- 52 Week High47.84
- 52 Week High Date04/22/26
- 52 Week Low3.43
- 52 Week Low Date06/20/25
Latest On Kodiak Sciences Inc
Key Stats
- Market Cap2.12B
- Shares Out62.58M
- 10 Day Average Volume0.63M
- Dividend-
- Dividend Yield-
- Beta2.21
Latest On Kodiak Sciences Inc
KEY STATS
- Open33.47
- Day High35.32
- Day Low32.64
- Prev Close33.22
- 52 Week High47.84
- 52 Week High Date04/22/26
- 52 Week Low3.43
- 52 Week Low Date06/20/25
- Market Cap2.12B
- Shares Out62.58M
- 10 Day Average Volume0.63M
- Dividend-
- Dividend Yield-
- Beta2.21
RATIOS/PROFITABILITY
- EPS (TTM)-4.17
- P/E (TTM)-8.11
- Fwd P/E (NTM)-12.01
- EBITDA (TTM)-215.358M
- ROE (TTM)-208.80%
- Revenue (TTM)-
- Gross Margin (TTM)-
- Net Margin (TTM)-
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date08/11/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREKodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to...
Victor Perlroth M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
John Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Address
1250 Page Mill Rd
Palo Alto, CA
94304
United States